AbCellera Biologics
ABCL
ABCL
190 hedge funds and large institutions have $1.17B invested in AbCellera Biologics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 75 increasing their positions, 37 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.21% more ownership
Funds ownership: 41.52% → 42.73% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4% less capital invested
Capital invested by funds: $1.22B → $1.17B (-$49.6M)
Holders
190
Holding in Top 10
7
Calls
$49.9M
Puts
$11.1M
Top Buyers
| 1 | +$106M | |
| 2 | +$16.5M | |
| 3 | +$14.9M | |
| 4 |
CC
Casdin Capital
New York
|
+$8.9M |
| 5 |
BlackRock
New York
|
+$7.36M |
Top Sellers
| 1 | -$115M | |
| 2 | -$34.2M | |
| 3 | -$20.6M | |
| 4 |
Renaissance Technologies
New York
|
-$10.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$7.95M |